ALK Fusion Probe

Location: San Francisco, CA
Date: 2021-02-23
ALK Gene Fusion Detection ProbeProduct Advantages:?1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.3.Reproducibility: Different laboratories test results are highly reproducibleProduct Description :Lung cancer, Anaplastic large cell lymphomaAbout ALKThe ALK gene encodes a transmembrane receptor tyrosine kinase (RTK). The ALK-NPM1 fusion protein was originally found in anaplastic large cell lymphoma and in other tumors including neuroblastoma and non-small cell lung cancer. The gene was found to be mutated, amplified, or rearranged, with chromosome rearrangements being the most common, resulting in ALK fusion with other genes including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3) , ALK / NPM1 (chromosome 5), ALK / SQSTM1 (chromosome 5), ALK / KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (X chromosome).?Probe DescriptionALK gene break apart probe uses orange labeled dye ALK gene (3 ' End) 2p23.2 region, and a green dye ALK gene (5' End) to mark 2p23.1-p23.2 region. ALK gene break apart probe can detect all ALK gene rearrangement, avoiding missed diagnosis caused by a single fusion gene (such as EML4-ALK). The 2013 edition of China anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer diagnosis expert consensus pointed out that adenocarcinoma, for age (60 years old), nonsmoking, EGFR, KRAS, HER2 or P53 in patients without NSCLC gene mutations, ALK gene positive rate is high as 30%~ 42%. Pathological studies suggest that the positive rate in signet-ring cell-containing mucinous or solid adenocarcinoma is higher than other types of lung adenocarcinoma. In 2013, CFDA approved XALKORI (Crizotinib) for targeted therapy of advanced ALK-positive non-small cell lung cancer, and the necessary condition for XALKORI (Crizotinib) drug treatment was FISH for the detection of ALK-positive non-small cell lung cancer. ALK-positive gene fusion patients are sensitive to XALKORI (Crizotinib) treatment.??Size SpecificationsReferences :l? Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.l? Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80.l? Von Laffert M, et al. (2013) Lung Cancer 81: 200-6.

Contact Info: